We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+2.63%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$2.47B
AUM Growth
-$242M
Cap. Flow
-$190M
Cap. Flow %
-7.68%
Top 10 Hldgs %
50.34%
Holding
119
New
24
Increased
30
Reduced
30
Closed
26

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$104M
2
VCEL icon
Vericel Corp
VCEL
+$63.4M
3
UTHR icon
United Therapeutics
UTHR
+$63.3M
4
KRYS icon
Krystal Biotech
KRYS
+$56.4M
5
PGNY icon
Progyny
PGNY
+$44.3M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$80.6M
2
FOLD
Amicus Therapeutics
FOLD
+$74.2M
3
CELC icon
Celcuity
CELC
+$57.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$39M
5
GSK icon
GSK
GSK
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
1
Krystal Biotech
KRYS
$10B
$298M 12.06%
1,153,087
+212,028
+23% +$56.4M
CELC icon
2
Celcuity
CELC
$4.47B
$147M 5.94%
1,284,378
-523,880
-29% -$57.1M
TGTX icon
3
TG Therapeutics
TGTX
$8.26B
$134M 5.42%
4,029,319
+890,007
+28% +$26.5M
PODD icon
4
Insulet
PODD
$11.3B
$118M 4.78%
562,500
+412,500
+275% +$104M
NVCR icon
5
NovoCure
NVCR
$1.85B
$114M 4.63%
10,492,391
+1,961,726
+23% +$24.5M
UTHR icon
6
United Therapeutics
UTHR
$26.7B
$111M 4.5%
187,187
+127,187
+212% +$63.3M
PRAX icon
7
Praxis Precision Medicines
PRAX
$8.86B
$106M 4.31%
330,517
-32,449
-9% -$10M
VCEL icon
8
Vericel Corp
VCEL
$2.36B
$82M 3.32%
2,549,079
+1,785,079
+234% +$63.4M
ALKS icon
9
Alkermes
ALKS
$8.81B
$69.7M 2.82%
1,970,864
+648,500
+49% +$20.1M
ANIP icon
10
ANI Pharmaceuticals
ANIP
$1.8B
$63.1M 2.55%
820,243
+334,000
+69% +$26.1M
GMED icon
11
Globus Medical
GMED
$10.3B
$62.9M 2.55%
729,467
-157,533
-18% -$14.1M
GERN icon
12
Geron
GERN
$924M
$61.8M 2.5%
41,508,659
+18,218,659
+78% +$27.7M
TWST icon
13
Twist Bioscience
TWST
$5.97B
$58.3M 2.36%
1,226,629
-635,173
-34% -$28.5M
EWTX icon
14
Edgewise Therapeutics
EWTX
$4.26B
$45.7M 1.85%
1,449,915
+539,915
+59% +$15.6M
BBNX
15
Beta Bionics
BBNX
$785M
$43.6M 1.77%
4,354,501
+1,819,936
+72% +$26.9M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$36.2B
$43.6M 1.76%
131,650
+61,650
+88% +$21M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$2.01B
$40.3M 1.63%
1,726,908
-520,202
-23% -$11.3M
INDV icon
18
Indivior Pharmaceuticals
INDV
$4.78B
$38.8M 1.57%
1,274,000
+1,174,000
+1,174% +$38.8M
NPCE icon
19
Neuropace
NPCE
$527M
$38.6M 1.56%
2,932,207
+228,999
+8% +$3.44M
LIVN icon
20
LivaNova
LIVN
$4.39B
$37M 1.5%
582,500
+15,000
+3% +$967K
MIRM icon
21
Mirum Pharmaceuticals
MIRM
$7.14B
$37M 1.5%
400,306
-173,308
-30% -$16.3M
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$11.4B
$36.8M 1.49%
650,572
-669,428
-51% -$39M
PGNY icon
23
Progyny
PGNY
$2.53B
$35.1M 1.42%
+2,067,000
New +$44.3M
INSP icon
24
Inspire Medical Systems
INSP
$1.51B
$29.7M 1.2%
576,299
+276,900
+92% +$19.4M
FOCL
25
EDAP TMS S.A.
FOCL
$213M
$27.2M 1.1%
7,309,254
– –
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Soleus Capital Management held 119 positions worth $2.47B, down 8.9% from $2.71B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management withdrew a net $190M in Q1 2026, closing 26 positions and reducing 30 holdings. Its most notable exit was Amicus Therapeutics, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 87% a quarter earlier.

Against the trend, Soleus Capital Management opened a new position in Progyny worth $35.1M.

  • Soleus Capital Management's largest Q1 2026 buy was Progyny: 2,067,000 shares worth $35.1M.
  • Soleus Capital Management added most to Insulet in Q1 2026, an estimated $104M increase.
  • Soleus Capital Management's biggest Q1 2026 reduction was DexCom, cutting an estimated $80.6M.
  • Soleus Capital Management fully exited Amicus Therapeutics in Q1 2026, selling an estimated $74.2M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $2.47B portfolio in Q1 2026.
  • Soleus Capital Management opened 24 new positions and closed 26 in Q1 2026.
  • Soleus Capital Management's portfolio value fell 8.9% quarter-over-quarter to $2.47B.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.